Thermo Fisher Scientific Inc. (NYSE:TMO) Given Average Rating of “Moderate Buy” by Analysts

Thermo Fisher Scientific Inc. (NYSE:TMO) has been assigned an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $602.1364.

Several analysts have weighed in on the stock. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 price target for the company. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective on the stock. Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. Piper Sandler began coverage on Thermo Fisher Scientific in a research report on Thursday, June 11th. They set a “neutral” rating and a $510.00 price target on the stock. Finally, Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Legacy Wealth Managment LLC ID increased its stake in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares during the period. Allied Private Wealth LLC purchased a new stake in Thermo Fisher Scientific in the second quarter worth $26,000. High Note Wealth LLC boosted its holdings in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at $28,000. Finally, JPL Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth about $28,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.1%

Shares of TMO opened at $526.72 on Monday. Thermo Fisher Scientific has a 1 year low of $403.36 and a 1 year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock has a 50 day simple moving average of $478.23 and a two-hundred day simple moving average of $516.03. The firm has a market cap of $195.74 billion, a P/E ratio of 28.96, a P/E/G ratio of 2.33 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the previous year, the business posted $5.15 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts forecast that Thermo Fisher Scientific will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.